Articles

Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status. Read More ›

In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death. Read More ›

Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant. Read More ›

NOVA clinical trial data outcomes were superior to the real-world outcomes for niraparib, highlighting the critical need for better understanding of variables impacting poly (ADP-ribose) polymerase (PARP) inhibitor outcomes in clinical practice. Read More ›

Olaparib maintenance monotherapy not only delays disease progression but also improves overall survival (OS) in women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation. Read More ›

Due to a variety of factors, first-line therapy with atezolizumab failed to demonstrate significant activity in patients with newly diagnosed stage III or stage IV ovarian cancer. Read More ›

Is subsequent chemotherapy less effective for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer who have been treated with olaparib as maintenance therapy? Here we discuss the latest findings from the SOLO2/ENGOT Ov-21 clinical trial. Read More ›

Despite substantial rates of intraoperative tumor spillages, patients with ovarian germ cell tumors (OGCTs) had an excellent prognosis, and adjuvant chemotherapy showed evidence of preventing disease recurrence. Read More ›

In patients with high-grade ovarian cancer harboring BRCA mutations and a confirmed response to rucaparib, BRCA homozygous deletion or rearrangement was associated with a significantly longer duration of response. Read More ›

Treatment with rucaparib was associated with improvements in progression-free survival, time to first subsequent treatment, and other post-progression efficacy end points. Read More ›